Guided Therapeutics (GTHP) FCF Payout Ratio (2023 - 2024)

Guided Therapeutics' (GTHP) quarterly FCF Payout Ratio came in at 0.26 in Q2 2024, up 60.77% quarter-over-quarter from 0.65 in Q1 2024.

Guided Therapeutics (GTHP) FCF Payout Ratio (2023 - 2024) Analysis & Trends

Guided Therapeutics has disclosed FCF Payout Ratio across 2 years of filings, most recently posting 0.26 for Q2 2024.

FCF Payout Ratio for Q2 2024 came in at 0.26, changed N/A year-over-year; the trailing twelve-month figure through Jun 2024 was 0.11 (down 209.28% YoY), and the FY2023 annual result was 0.04, up 52.99% from the prior year.
FCF Payout Ratio came in at 0.26 for Q2 2024 at Guided Therapeutics, up from 0.65 in the prior quarter.
In the past five years, FCF Payout Ratio ranged from a high of 0.13 in Q1 2023 to a low of 0.65 in Q1 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	FCF Cover (Qtr)
1	Abbott Laboratories	154.42 Bn	147.76 Bn	6.27 Bn	1.20
2	Stryker	118.12 Bn	115.25 Bn	3.81 Bn	0.81
3	Medtronic	101.72 Bn	93.55 Bn	5.76 Bn	0.40
4	Boston Scientific	67.19 Bn	65.98 Bn	3.61 Bn	-
5	Edwards Lifesciences	50.69 Bn	47.02 Bn	1.29 Bn	-
6	Koninklijke Philips	29.38 Bn	26.07 Bn	2.07 Bn	-
7	Dexcom	28.09 Bn	26.97 Bn	750.30 Mn	-
8	GE HealthCare Technologies	28.08 Bn	26.02 Bn	1.98 Bn	0.08
9	Steris	19.80 Bn	19.37 Bn	697.10 Mn	0.25
10	Guided Therapeutics	-	-	458,000.00	-

Download Data